प्रौद्योगिकी प्रस्ताव
- Reusable Heterogeneous Catalyst
Batch Size: 10 kg
Reduced water footprint
Racemic Yield 85%
Efficient downstream protocol
Reusable Solvent
अनुप्रयोग
Treatment of Type-2 Diabetes
वर्तमान स्थिती
मूल्य प्रस्ताव
•Inexpensive
heterogeneous
catalyst
•Scalable
&
Cost-effective Process
•Racemic
Yield
of up to 85%
•Significant
reduction
in wastewater
Generation
•Improved
solubility
limitations
•Less
Downstreaming steps
विशेषताएँ
üReusable
novel Heterogeneous Catalyst
ü100%
Key Starting Material conversion
üHighly
selective
(97%) process
üHigh
Racemic
yields (up to 85%)
üLess
effluent
discharge
üReduced
reaction
time
üReusable
solvent
अन्य सूचना
बाज़ार संभाव्यता
TWYMEEG® net sales in Japan has reached JPY 5 billion (USD 33 million) in 2024
- India has approved Imeglimin in January 2023
पृष्ठभूमि
•India's
Type-2 diabetes cases may reach 134 million by 2045
•Prolonged
use
of Metformin can cause gastro
intolerance & vit B-12
deficiency
•Imeglimin
(TWYMEEG®), a novel & safer alternative, was launched in Japan.
•Our technology
offering improves its synthesis & economics
by addressing existing issues of solubility limitations, longer reaction time,
more down-streaming steps
& water
footprints
etc.
